Hologic buys Accessa Health for $80M

Hologic (NSDQ:HOLX) announced that it acquired fibroid treatment developer Acessa Health in a deal worth approximately $80 million.

Austin, Texas-based Acessa markets the Acessa ProVu fully integrated laparoscopic system for combining radiofrequency ablation with intra-abdominal ultrasound visualization and guidance mapping for treating women with symptomatic, benign uterine fibroids.

Marlborough, Mass.-based Hologic said in a news release that the Acessa ProVu system will complement its market-leading MyoSure products designed for the hysteroscopic removal of fibroids found in the uterine cavity.

The deal includes $80 million in cash, plus additional contingent payments based on future revenue growth, according to the release. Hologic estimates that Acessa Health will generate approximately $13 million in revenue for fiscal 2021, producing a slightly dilutive impact on Hologic’s non-Gaap earnings per share for the year, then a break-even in 2022, …

Read more
  • 0

Acessa Health appoints three new executives to leadership team

Acessa Health this week announced it added three new executives to its team.

Shonu Gandhi was appointed VP of market access and clinical strategy. Her role will be focusing on improving patient access to the Acessa procedure by expanding payer coverage and clinical evidence.

Gandhi has more than 10 years of experience and most recently served as the leader of the inaugural business development team at Dell Medical School at the University of Texas, Austin.

Alfred Macdaniel joins the company as chief strategy officer and general counsel. He has more than 18 years of financial, legal, OUS market expansion and merger and acquisition expertise. He has held a number of leadership positions at TVA Medical, including chief financial officer, chief compliance officer and general counsel.

Carolyn Amato has been appointed as senior VP of commercial and will be responsible for leading Acessa Health’s sales and marketing organizations to accelerate pati…

Read more
  • 0